...
Interpreting Medical Literature
June 7, 2019

Featuring Dr. Jennie Clarke and Dr. Joslyn Kirby This morning Dr. Jennie Clarke and Dr. Joslyn Kirby gave a wonderful presentation reviewing pertinent medical literature from the last year applicable to current dermatology practice. Confirming what most in the dermatology field already believed, a recent JAMA Dermatology article revealed total unprotected sun exposure is significantly

...
Use of DPP-4 Inhibitors May Increase Risk of Developing Bullous Pemphigoid in Diabetic Patients
December 3, 2018

Dipeptidyl-Peptidase 4 Inhibitors (DPP-4), belong to a class of anti-hyperglycemic agents indicated for improving glycemic control in patients with type-2 diabetes. As their use has increased, so has the number of cases of Bullous Pemphigoid (BP), a chronic skin disorder characterized by blisters, hives and itching. A recent study used a case-control method to answer

...
Doxycycline or Prednisolone? Which Is Better to Treat Bullous Pemphigoid
March 5, 2018

Bullous pemphigoid (BP) is a relatively rare blistering skin disorder that causes intense itching, erythema, blisters and risk for secondary infection, mostly affecting patients older than 70. A recent clinical trial, The Bullous Pemphigoid Steroids and Tetracyclines (BLISTER), compared strategies of starting treatment with doxycycline or with oral prednisolone. The goals were to determine whether

jojobetjojobet girişpusulabetpusulabet girişgalabetgalabet girişJojobetJojobet GirişJojobetJojobet GirişJojobetJojobet GirişJOJOBET